Nothing Special   »   [go: up one dir, main page]

WO2021210920A1 - Method for producing ramelteon, and intermediate compound used for same - Google Patents

Method for producing ramelteon, and intermediate compound used for same Download PDF

Info

Publication number
WO2021210920A1
WO2021210920A1 PCT/KR2021/004719 KR2021004719W WO2021210920A1 WO 2021210920 A1 WO2021210920 A1 WO 2021210920A1 KR 2021004719 W KR2021004719 W KR 2021004719W WO 2021210920 A1 WO2021210920 A1 WO 2021210920A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
hydrochloride
isomer
present
Prior art date
Application number
PCT/KR2021/004719
Other languages
French (fr)
Korean (ko)
Inventor
유형철
김재선
정중근
손연우
이성홍
강동우
양현준
전재훈
김경현
Original Assignee
제이투에이치바이오텍 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제이투에이치바이오텍 주식회사 filed Critical 제이투에이치바이오텍 주식회사
Publication of WO2021210920A1 publication Critical patent/WO2021210920A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Definitions

  • the present invention relates to a method for producing a ramelteon.
  • the present invention also relates to novel intermediate compounds for use in the preparation of ramelteon.
  • Ramelteon is a medicinal ingredient approved for the treatment of chronic insomnia. Most of the Ramelteon processes are chiral reduction by metal catalysts of double bonds. A typical process is as follows, and so far, it is known that the chiral reduction process using such a metal catalyst is the most effective process.
  • the chiral reduction method using the metal catalyst is a process that requires a high-pressure hydrogen reaction of about 50 atmospheres, and has a disadvantage in that it may be limited in mass production process.
  • PCT patent WO2008/151170 discloses a method of optically resolving a non-optically active amine compound using chiral amine or chiral acid without chiral reduction as in the following process.
  • the problem to be solved by the present invention is to provide a method for manufacturing ramelteon that is economical and can be performed under mild conditions.
  • Another problem to be solved by the present invention is to provide an intermediate compound that can be used for the preparation of ramelteon.
  • the present invention provides a method for producing a ramelteon (ramelteon), characterized in that using the (R) -isomer of the following formula (1).
  • the present invention is a racemic compound of Formula 1 1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-carboxylic acid by optical resolution (optical resolution) of Formula 1 ( R) - obtaining the isomer.
  • the preparation method of the present invention provides a preparation method characterized in that the (S)-isomer of Formula 1 is recovered, racemized, and reused.
  • the production method of the present invention can not only react under mild conditions, but also economical production can be possible by performing chiral separation at the beginning of the production step.
  • the production method of the present invention is economical by using the (S)-isomer of formula (1) again.
  • the compound of Formula 1 of the present invention has a very high acidity of H, which is connected to the carbon atom to which the COOH group is connected, so that there is no need to use a relatively strong base in the racemization process, and consequently, there is a significant risk of impurities occurring during the racemization process. as low as
  • the optical splitting is performed by forming a chiral amine salt, and as a chiral amine, (S)-phenylethylamine, L-(-)- ⁇ -Amino- ⁇ -caprolactam hydrochloride, (S)-(-)-1-Amino-2-propanol, L-Aspartic acid, (S)-N-Benzyl-1-(1-naphthyl)ethylamine hydrochloride, (+ )-Bis[(R)-1-phenylethyl]amine hydrochloride, (+)-Cinchonine, (R)- ⁇ -Methyl-4-nitrobenzylamine hydrochloride or (S)-(-)-1-(2-Naphthyl)ethylamine This can be used. More preferably, the chiral amine is (S)-phenylethylamine.
  • the preparation method of the present invention uses the difference in solubility between the (S)-isomer chiral amine salt and (R)-isomer chiral amine salt produced by reacting the compound of Formula 1 with a chiral amine to separate them, and then (S)- The isomer chiral amine salt is racemized again to obtain a compound of formula (1).
  • the ramelteon production method of the present invention is a racemic compound 1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-carboxylic acid optical resolution (optical resolution) to obtain a (R)-isomer of Formula 1 and racemizing the separated (S)-isomer of Formula 1 again to obtain a compound of Formula 1, wherein the obtained compound of Formula 1 is used in the manufacturing method of the invention.
  • optical resolution optical resolution
  • the preparation method of the present invention includes the step of re-using the chiral amine salt of the (S)-isomer of Formula 1 recovered during the optical resolution process by racemizing it.
  • the chiral amine salt of the (S)-isomer of Formula 1 is racemized under a base, and the base includes sodium hydroxide (NaOH), potassium hydroxide (KOH), and potassium tert-butoxide (KOtBu).
  • NaOMe sodium methoxide
  • the base includes sodium hydroxide (NaOH), potassium hydroxide (KOH), and potassium tert-butoxide (KOtBu).
  • NaOMe sodium methoxide
  • a mixture thereof may be used.
  • the production method of the present invention is a racemic compound 1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-carboxylic acid optical resolution (optical resolution) to obtain an (R)-isomer of Formula 1; re-racemizing the separated (S)-isomer of Formula 1 to obtain a compound of Formula 1; and a process of preparing the compound of Formula 3 as the (S)-isomer of Formula 1 prepared by Scheme 1. This reaction is shown in Scheme 2 below.
  • the compound of Formula 3 is (S)-2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8 -yl)ethan-1-amine (TIFEA) or a salt thereof comprises the step of preparing, and then further reacting with propionyl chloride to prepare the target compound of the present invention, ramelteon.
  • the preparation method of the present invention includes the steps represented by Scheme 3 as follows.
  • the TIFEA compound or a salt thereof used in Scheme 3 may be prepared from TIFM using, for example, the method shown in Scheme 4 below.
  • the compound of Formula 1 can be prepared by reacting 1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-carbonitrile (TIFN) with a base.
  • TIFN 1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-carbonitrile
  • base NaOH (sodium hydroxide), KOH (potassium hydroxide), LiOH (lithium hydroxide), Ba(OH) 2 (Barium Hydroxide) or a mixture thereof may be used.
  • NaOH sodium hydroxide
  • KOH potassium hydroxide
  • LiOH lithium hydroxide
  • Ba(OH) 2 Barium Hydroxide
  • it may be prepared as in Scheme 5 below using NaOH.
  • TIFN 1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-carbonitrile
  • the present invention also provides a compound of Formula 1, which can be usefully used in the preparation of ramelteon.
  • the present invention also provides (R)-isomeric forms and/or (S)-isomeric forms of the compound of Formula 1 above. According to the preparation method of the present invention, these isomerically pure compounds can be usefully used in the preparation of ramelteon.
  • the isomeric compounds referred to in the present invention exist as isomerically pure compounds. For example, substantially free of other stereoisomers (eg, at least 80% ee, at least 85% ee, at least 90% ee, at least 95% ee, at least 97% ee, or at least 99% ee). do.
  • the present invention also provides a chiral amine salt compound of the following formula (2), which can be usefully used in the preparation of ramelteon.
  • the chiral amine salt is (S)-phenylethylamine, L-(-)- ⁇ -Amino- ⁇ -caprolactam hydrochloride, (S)-(-)-1-Amino-2-propanol, L-Aspartic acid, (S )-N-Benzyl-1-(1-naphthyl)ethylamine hydrochloride, (+)-Bis[(R)-1-phenylethyl]amine hydrochloride, (+)-Cinchonine, (R)- ⁇ -Methyl-4-nitrobenzylamine It is formed from hydrochloride or (S)-(-)-1-(2-Naphthyl)ethylamine.
  • the present invention also provides an (R)-isomer compound represented by the following formula (3).
  • the compound of Formula 3 below may be usefully used in the preparation of ramelteon.
  • the production method of the present invention can be used again by racemizing the (S)-isomer that is not used after optical resolution, and the yield improvement can be expected because the process is simple.
  • the production method of the present invention can be carried out under relatively mild conditions.
  • Compound TIFC preparation base, e.g. NaOH
  • the filtrate of the above resolution process was collected and concentrated, and water (810 mL) and sodium hydroxide (59.7 g, 1.49 mol) were added and stirred for 30 minutes.
  • the aqueous solution was washed with methyl tert -butyl ether (324 mL) and stirred. Cool the reaction and wash with methyl tert -butyl ether (230 mL x 2).
  • the aqueous layer was treated with activated carbon (15.0 g) and acidified to recover compound TIFC (89.1 g, 0.436 mol).
  • Tetrahydrofuran (225 mL) and water (315 mL) were added to the compound TIFEA (90.0 g, 0.375 mol), and 30% sodium hydroxide (aqueous solution, 85.0 mL, 0.848 mol) was added.
  • the reaction solution was cooled to 10 ⁇ 15 °C, propionyl chloride (40.0 g, 0.432 mol) was slowly added.
  • the mixture was further stirred at 15-25 °C for 1 hour.
  • water (720 mL) to the reaction solution it was cooled to 0-5 °C, and the resulting solid was filtered.
  • the obtained solid was recrystallized and purified in a mixed solvent of ethanol and water to obtain Ramelteon (87.6 g, 0.338 mol).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention provides: a novel method for producing Ramelteon; and an intermediate compound used for the production method. The production method according to the present invention is cost-effective, and can be used to produce Ramelteon under relatively mild conditions.

Description

라멜테온의 제조 방법 및 이러한 제조 방법에 이용되는 중간체 화합물Method for preparing ramelteon and intermediate compound used in such method
본 출원은 2020년 4월 16일에 출원된 한국특허출원 제10-2020-0046248호에 기초한 우선권을 주장하며, 해당 출원의 명세서 및 도면에 개시된 모든 내용은 본 출원에 원용된다.This application claims priority based on Korean Patent Application No. 10-2020-0046248 filed on April 16, 2020, and all contents disclosed in the specification and drawings of the application are incorporated herein by reference.
본 발명은 라멜테온의 제조 방법에 관한 것이다. 본 발명은 또한 라멜테온의 제조에 이용되는 새로운 중간체 화합물들에 관한 것이다.The present invention relates to a method for producing a ramelteon. The present invention also relates to novel intermediate compounds for use in the preparation of ramelteon.
라멜테온(ramelteon)은 만성불면증 질환 치료제로 허가 받은 의약 성분이다. 대부분의 Ramelteon 제법은 이중 결합의 금속 촉매에 의한 chiral reduction이다. 대표적인 공정은 아래와 같으며, 현재까지는 이러한 금속 촉매를 사용한 chiral reduction 공정이 가장 효과적인 공정인 것으로 알려져 있다.Ramelteon is a medicinal ingredient approved for the treatment of chronic insomnia. Most of the Ramelteon processes are chiral reduction by metal catalysts of double bonds. A typical process is as follows, and so far, it is known that the chiral reduction process using such a metal catalyst is the most effective process.
Figure PCTKR2021004719-appb-img-000001
Figure PCTKR2021004719-appb-img-000001
그러나, 상기 금속 촉매를 사용한 chiral reduction 방법은 대략 50기압 수준의 고압 수소 반응을 필요로 하는 공정으로 대량 생산 공정화에 제한이 따를 수 있는 단점이 있다.However, the chiral reduction method using the metal catalyst is a process that requires a high-pressure hydrogen reaction of about 50 atmospheres, and has a disadvantage in that it may be limited in mass production process.
또한 PCT 특허 WO2008/151170에서는 아래 공정과 같이 chiral reduction 없이 비광학활성 아민체를 chiral amine이나 chiral acid를 사용하여 광학분할(resolution)하는 방법을 개시하고 있다.In addition, PCT patent WO2008/151170 discloses a method of optically resolving a non-optically active amine compound using chiral amine or chiral acid without chiral reduction as in the following process.
Figure PCTKR2021004719-appb-img-000002
Figure PCTKR2021004719-appb-img-000002
그러나, 상기 방법의 경우 resolution 과정에서 얻은 R-isomer 외에 반대 광학활성을 갖는 S-isomer의 손실이 불가피하여 chiral reduction 공정을 이용한 기존 특허 공정 대비 경제성이 떨어진다.However, in the case of the above method, in addition to the R-isomer obtained in the resolution process, the loss of the S-isomer having the opposite optical activity is inevitable, so the economic feasibility is inferior compared to the existing patented process using the chiral reduction process.
따라서 본 발명이 해결하고자 하는 과제는 경제적이며, 온화한 조건에서 수행 가능한 라멜테온의 제조 방법을 제공하는 것이다. 본 발명이 해결하고자 하는 다른 과제는 라멜테온의 제조에 이용될 수 있는 중간체 화합물을 제공하는 것이다.Therefore, the problem to be solved by the present invention is to provide a method for manufacturing ramelteon that is economical and can be performed under mild conditions. Another problem to be solved by the present invention is to provide an intermediate compound that can be used for the preparation of ramelteon.
상기 과제를 해결하기 위하여, 본 발명은 하기 화학식 1의 (R)-이성질체를 이용하는 것을 특징으로 하는 라멜테온(ramelteon)의 제조 방법을 제공한다.In order to solve the above problems, the present invention provides a method for producing a ramelteon (ramelteon), characterized in that using the (R) -isomer of the following formula (1).
[화학식 1][Formula 1]
Figure PCTKR2021004719-appb-img-000003
Figure PCTKR2021004719-appb-img-000003
특히, 본 발명은 화학식 1의 라세믹 화합물인 1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-carboxylic acid를 광학분할(optical resolution)하여 화학식 1의 (R)-이성질체를 획득하는 단계를 포함하는, 제조 방법을 제공한다.In particular, the present invention is a racemic compound of Formula 1 1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-carboxylic acid by optical resolution (optical resolution) of Formula 1 ( R) - obtaining the isomer.
바람직하게, 본 발명의 제조 방법은 화학식 1의 (S)-이성질체를 회수하고 라세미화(racemize)하여 다시 이용하는 것을 특징으로 하는 제조 방법을 제공한다.Preferably, the preparation method of the present invention provides a preparation method characterized in that the (S)-isomer of Formula 1 is recovered, racemized, and reused.
본 발명의 제조 방법은 온화한 조건에서 반응 가능할 뿐만 아니라, 카이럴 분리를 제조 단계 초기에 수행함으로써 경제적인 생산이 가능할 수 있다. 또한, 본 발명의 제조 방법은 화학식 1의 (S)-이성질체를 다시 이용함으로써 경제적이다. 본 발명의 화학식 1의 화합물은, COOH기가 연결된 탄소 원자에 같이 연결되어 있는 H의 산도가 매우 높아 라세미화 과정에서 상대적으로 강염기를 사용할 필요가 없고, 결과적으로 라세미화 과정에서 불순물이 생기는 우려가 획기적으로 낮다. The production method of the present invention can not only react under mild conditions, but also economical production can be possible by performing chiral separation at the beginning of the production step. In addition, the production method of the present invention is economical by using the (S)-isomer of formula (1) again. The compound of Formula 1 of the present invention has a very high acidity of H, which is connected to the carbon atom to which the COOH group is connected, so that there is no need to use a relatively strong base in the racemization process, and consequently, there is a significant risk of impurities occurring during the racemization process. as low as
바람직하게, 본 발명의 제조 방법에 있어 상기 광학분할은 카이럴 아민 염(chiral amine salt)을 형성하여 수행되며, 카이럴 아민(chiral amine)으로는 (S)-phenylethylamine, L-(-)-α-Amino-ε-caprolactam hydrochloride, (S)-(-)-1-Amino-2-propanol, L-Aspartic acid, (S)-N-Benzyl-1-(1-naphthyl)ethylamine hydrochloride, (+)-Bis[(R)-1-phenylethyl]amine hydrochloride, (+)-Cinchonine, (R)-α-Methyl-4-nitrobenzylamine hydrochloride 또는 (S)-(-)-1-(2-Naphthyl)ethylamine이 이용될 수 있다. 더욱 바람직하게, 상기 카이럴 아민은 (S)-phenylethylamine이다. Preferably, in the preparation method of the present invention, the optical splitting is performed by forming a chiral amine salt, and as a chiral amine, (S)-phenylethylamine, L-(-)- α-Amino-ε-caprolactam hydrochloride, (S)-(-)-1-Amino-2-propanol, L-Aspartic acid, (S)-N-Benzyl-1-(1-naphthyl)ethylamine hydrochloride, (+ )-Bis[(R)-1-phenylethyl]amine hydrochloride, (+)-Cinchonine, (R)-α-Methyl-4-nitrobenzylamine hydrochloride or (S)-(-)-1-(2-Naphthyl)ethylamine This can be used. More preferably, the chiral amine is (S)-phenylethylamine.
즉, 본 발명의 제조 방법은 화학식 1의 화합물에 카이럴 아민을 반응시켜 생성되는 (S)-이성질체 카이럴 아민 염과 (R)-이성질체 카이럴 아민 염의 용해도 차이를 이용해 양자를 분리하고, 이후 (S)-이성질체 카이럴 아민 염을 다시 라세미화하여 화학식 1의 화합물로 수득하는 과정을 거치게 된다.That is, the preparation method of the present invention uses the difference in solubility between the (S)-isomer chiral amine salt and (R)-isomer chiral amine salt produced by reacting the compound of Formula 1 with a chiral amine to separate them, and then (S)- The isomer chiral amine salt is racemized again to obtain a compound of formula (1).
따라서, 바람직하게, 본 발명의 라멜테온 제조 방법은 라세믹 화합물인 1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-carboxylic acid를 광학분할(optical resolution)하여 화학식 1의 (R)-이성질체를 획득하는 단계 및 분리된 화학식 1의 (S)-이성질체를 다시 라세미화하여 화학식 1의 화합물을 수득하는 단계를 포함하며, 수득된 화학식 1의 화합물은 다시 본 발명의 제조 방법에 이용된다. 이를 반응식으로 나타내면 다음과 같다. Therefore, preferably, the ramelteon production method of the present invention is a racemic compound 1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-carboxylic acid optical resolution (optical resolution) to obtain a (R)-isomer of Formula 1 and racemizing the separated (S)-isomer of Formula 1 again to obtain a compound of Formula 1, wherein the obtained compound of Formula 1 is used in the manufacturing method of the invention. This can be expressed as a reaction equation as follows.
[반응식 1][Scheme 1]
Figure PCTKR2021004719-appb-img-000004
Figure PCTKR2021004719-appb-img-000004
본 발명의 일 태양에서, 본 발명의 제조 방법은 광학분할 과정에서 회수되는 화학식 1의 (S)-이성질체의 카이럴 아민 염을 라세미화(ramcemize)하여 다시 이용하는 단계를 포함한다. In one aspect of the present invention, the preparation method of the present invention includes the step of re-using the chiral amine salt of the (S)-isomer of Formula 1 recovered during the optical resolution process by racemizing it.
본 발명의 일 태양에 있어, 화학식 1의 (S)-이성질체의 카이럴 아민 염은 염기 하에서 라세미화되며, 염기로는 NaOH (sodium hydroxide), KOH (potassium hydroxide), KOtBu (potassium tert-butoxide), NaOMe (sodium methoxide) 또는 이들의 혼합물이 이용될 수 있다. In one aspect of the present invention, the chiral amine salt of the (S)-isomer of Formula 1 is racemized under a base, and the base includes sodium hydroxide (NaOH), potassium hydroxide (KOH), and potassium tert-butoxide (KOtBu). , NaOMe (sodium methoxide) or a mixture thereof may be used.
본 발명의 일 태양에서, 본 발명의 제조 방법은 라세믹 화합물인 1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-carboxylic acid를 광학분할(optical resolution)하여 화학식 1의 (R)-이성질체를 획득하는 단계; 분리된 화학식 1의 (S)-이성질체를 다시 라세미화하여 화학식 1의 화합물을 수득하는 단계; 및 반응식 1로 만들어진 화학식 1의 (S)-이성질체로 화학식 3의 화합물로 제조하는 과정을 포함한다. 이러한 반응은 하기 반응식 2와 같다. In one aspect of the present invention, the production method of the present invention is a racemic compound 1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-carboxylic acid optical resolution (optical resolution) to obtain an (R)-isomer of Formula 1; re-racemizing the separated (S)-isomer of Formula 1 to obtain a compound of Formula 1; and a process of preparing the compound of Formula 3 as the (S)-isomer of Formula 1 prepared by Scheme 1. This reaction is shown in Scheme 2 below.
[화학식 1][Formula 1]
Figure PCTKR2021004719-appb-img-000005
Figure PCTKR2021004719-appb-img-000005
[화학식 3][Formula 3]
Figure PCTKR2021004719-appb-img-000006
Figure PCTKR2021004719-appb-img-000006
[반응식 2][Scheme 2]
Figure PCTKR2021004719-appb-img-000007
Figure PCTKR2021004719-appb-img-000007
본 발명의 일 태양에 있어, 본 발명의 제조 방법은 상기 화학식 3의 화합물을 (S)-2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethan-1-amine (TIFEA) 또는 이의 염(salt)으로 제조하는 단계를 포함하며, 이후 propionyl chloride와 추가로 반응시켜 본 발명의 목적 화합물인 라멜테온을 제조하는 단계를 포함한다. In one aspect of the present invention, in the preparation method of the present invention, the compound of Formula 3 is (S)-2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8 -yl)ethan-1-amine (TIFEA) or a salt thereof comprises the step of preparing, and then further reacting with propionyl chloride to prepare the target compound of the present invention, ramelteon.
본 발명의 일 태양에 있어, 본 발명의 제조 방법은 다음과 같은 반응식 3으로 표시되는 단계들을 포함한다. In one aspect of the present invention, the preparation method of the present invention includes the steps represented by Scheme 3 as follows.
[반응식 3][Scheme 3]
Figure PCTKR2021004719-appb-img-000008
Figure PCTKR2021004719-appb-img-000008
본 발명의 일 태양에 있어, 상기 반응식 3에서 이용되는 TIFEA 화합물 또는 이의 염은 예를 들어, 하기 반응식 4와 같은 방법을 이용하여 TIFM으로부터 제조될 수 있다. In one aspect of the present invention, the TIFEA compound or a salt thereof used in Scheme 3 may be prepared from TIFM using, for example, the method shown in Scheme 4 below.
[반응식 4][Scheme 4]
Figure PCTKR2021004719-appb-img-000009
Figure PCTKR2021004719-appb-img-000009
본 발명의 일 태양에 있어, 상기 화학식 1의 화합물은 1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-carbonitrile (TIFN)을 염기와 반응시켜 제조할 수 있으며, 염기로는 앞서 언급된 NaOH (sodium hydroxide), KOH (potassium hydroxide), LiOH(lithium Hydroxide), Ba(OH) 2 (Barium Hydroxide) 또는 이들의 혼합물이 사용될 수 있다. 예를 들어, NaOH를 이용하여 하기 반응식 5와 같이 제조될 수 있다. In one embodiment of the present invention, the compound of Formula 1 can be prepared by reacting 1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-carbonitrile (TIFN) with a base. In addition, as the base, NaOH (sodium hydroxide), KOH (potassium hydroxide), LiOH (lithium hydroxide), Ba(OH) 2 (Barium Hydroxide) or a mixture thereof may be used. For example, it may be prepared as in Scheme 5 below using NaOH.
[반응식 5][Scheme 5]
Figure PCTKR2021004719-appb-img-000010
Figure PCTKR2021004719-appb-img-000010
본 발명의 일 태양에 있어, 1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-carbonitrile (TIFN)은 본 발명이 속한 분야에 있어 공지된 방법들을 이용하여 제조할 수 있다. 예를 들어, 본 발명의 제조 방법에 있어 TIFN은 하기 반응식 6과 같은 방법으로 제조된다. In one aspect of the present invention, 1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-carbonitrile (TIFN) is prepared using methods known in the art. can be manufactured. For example, in the preparation method of the present invention, TIFN is prepared by the method shown in Scheme 6 below.
[반응식 6][Scheme 6]
Figure PCTKR2021004719-appb-img-000011
Figure PCTKR2021004719-appb-img-000011
본 발명은 또한 라멜테온의 제조에 유용하게 사용될 수 있는, 하기 화학식 1의 화합물을 제공한다.The present invention also provides a compound of Formula 1, which can be usefully used in the preparation of ramelteon.
[화학식 1][Formula 1]
Figure PCTKR2021004719-appb-img-000012
Figure PCTKR2021004719-appb-img-000012
본 발명은 또한, 상기 화학식 1 화합물의 (R)-이성질체 형태 및/또는 (S)-이성질체 형태의 화합물을 제공한다. 본 발명의 제조 방법에 따를 때, 이러한 이성질체적으로 순수한 화합물들은 라멜테온의 제조에 유용하게 이용될 수 있다. The present invention also provides (R)-isomeric forms and/or (S)-isomeric forms of the compound of Formula 1 above. According to the preparation method of the present invention, these isomerically pure compounds can be usefully used in the preparation of ramelteon.
본 발명에서 언급된 이성질체 화합물들은 이성질체적으로 순수한 화합물들로 존재한다. 예를 들어, 다른 입체이성질체가 실질적으로 없는(예를 들어, 80% ee 이상, 85% ee 이상, 90% ee 이상, 95% ee 이상, 97% ee 이상, 또는 99% ee 이상) 상태로 존재한다. The isomeric compounds referred to in the present invention exist as isomerically pure compounds. For example, substantially free of other stereoisomers (eg, at least 80% ee, at least 85% ee, at least 90% ee, at least 95% ee, at least 97% ee, or at least 99% ee). do.
본 발명은 또한 라멜테온의 제조에 유용하게 사용될 수 있는, 하기 화학식 2의 카이럴 아민 염(chiral amine salt) 화합물을 제공한다. The present invention also provides a chiral amine salt compound of the following formula (2), which can be usefully used in the preparation of ramelteon.
[화학식 2][Formula 2]
Figure PCTKR2021004719-appb-img-000013
Figure PCTKR2021004719-appb-img-000013
상기 카이럴 아민 염은 (S)-phenylethylamine, L-(-)-α-Amino-ε-caprolactam hydrochloride, (S)-(-)-1-Amino-2-propanol, L-Aspartic acid, (S)-N-Benzyl-1-(1-naphthyl)ethylamine hydrochloride, (+)-Bis[(R)-1-phenylethyl]amine hydrochloride, (+)-Cinchonine, (R)-α-Methyl-4-nitrobenzylamine hydrochloride 또는 (S)-(-)-1-(2-Naphthyl)ethylamine으로 형성된다. The chiral amine salt is (S)-phenylethylamine, L-(-)-α-Amino-ε-caprolactam hydrochloride, (S)-(-)-1-Amino-2-propanol, L-Aspartic acid, (S )-N-Benzyl-1-(1-naphthyl)ethylamine hydrochloride, (+)-Bis[(R)-1-phenylethyl]amine hydrochloride, (+)-Cinchonine, (R)-α-Methyl-4-nitrobenzylamine It is formed from hydrochloride or (S)-(-)-1-(2-Naphthyl)ethylamine.
본 발명의 일 태양에 있어, 본 발명은 또한 하기 화학식 3의 (R)-이성질체 화합물을 제공한다. 하기 화학식 3의 화합물은 라멜테온의 제조에 유용하게 이용될 수 있다.In one aspect of the present invention, the present invention also provides an (R)-isomer compound represented by the following formula (3). The compound of Formula 3 below may be usefully used in the preparation of ramelteon.
[화학식 3][Formula 3]
Figure PCTKR2021004719-appb-img-000014
Figure PCTKR2021004719-appb-img-000014
본 발명의 제조 방법은 광학분할 후 이용되지 않은 (S)-이성질체를 라세미화하여 다시 이용 가능하며, 공정이 단순하여 수율 향상을 기대할 수 있다. 또, 본 발명의 제조 방법은 상대적으로 온화한 조건에서 수행 가능하다.The production method of the present invention can be used again by racemizing the (S)-isomer that is not used after optical resolution, and the yield improvement can be expected because the process is simple. In addition, the production method of the present invention can be carried out under relatively mild conditions.
이하, 본 발명의 이해를 돕기 위하여 실시예 등을 들어 상세하게 설명하기로 한다. 그러나, 본 발명에 따른 실시예들은 여러 가지 다른 형태로 변형될 수 있으며, 본 발명의 범위가 하기 실시예들에 한정되는 것으로 해석되어서는 안 된다. 본 발명의 실시예들은 본 발명이 속한 분야에서 평균적인 지식을 가진 자에게 본 발명을 보다 완전하게 설명하기 위해 제공되는 것이다.Hereinafter, examples and the like will be described in detail to help the understanding of the present invention. However, the embodiments according to the present invention may be modified in various other forms, and the scope of the present invention should not be construed as being limited to the following examples. The embodiments of the present invention are provided to more completely explain the present invention to those of ordinary skill in the art to which the present invention pertains.
화합물 TIFO 제조 (NaBH 4)Compound TIFO preparation (NaBH 4 )
Figure PCTKR2021004719-appb-img-000015
Figure PCTKR2021004719-appb-img-000015
Sodium borohydride (43.4 g, 1.15 mol)를 화합물 TIF (중국 reliable chem사 제조, 200 g, 1.15 mmol)의 ethanol (900 mL), tetrahydrofuran (300 mL) 용액에 투입하고 70 ℃에서 2시간 동안 교반하였다. 반응이 완료되면 5~10 ℃로 냉각하고 진한 hydrochloric acid (113 g, 1.15 mol)를 투입한다. 반응물을 물 (1.6 L)로 희석하고 dichloromethane (800 mL, 400 mL)으로 추출하였다. 합해진 유기층을 포화 sodium bicarbonate 수용액 (600 mL)로 세척하고 magnesium sulfate로 건조한 후 여과 농축하였다. 농축 잔류물에 toluene (200 mL)을 투입 후 78~83 ℃로 승온하고 heptane (1.6 L)을 투입하였다. 반응물을 3~6 ℃로 천천히 냉각하고 생성된 결정을 여과하여 화합물 TIFO (198 g, 1.12 mol)를 얻었다.Sodium borohydride (43.4 g, 1.15 mol) was added to a solution of the compound TIF (manufactured by Reliable Chem, China, 200 g, 1.15 mmol) in ethanol (900 mL) and tetrahydrofuran (300 mL) and stirred at 70 °C for 2 hours. When the reaction is complete, it is cooled to 5-10 ℃, and concentrated hydrochloric acid (113 g, 1.15 mol) is added. The reaction was diluted with water (1.6 L) and extracted with dichloromethane (800 mL, 400 mL). The combined organic layer was washed with a saturated aqueous sodium bicarbonate solution (600 mL), dried over magnesium sulfate, and then concentrated by filtration. Toluene (200 mL) was added to the concentrated residue, the temperature was raised to 78~83 ℃, and heptane (1.6 L) was added. The reaction mass was cooled slowly to 3-6 °C, and the resulting crystals were filtered to obtain compound TIFO (198 g, 1.12 mol).
화합물 TIFCl 제조 (PCl 3)Preparation of compound TIFCl (PCl 3 )
Figure PCTKR2021004719-appb-img-000016
Figure PCTKR2021004719-appb-img-000016
화합물 TIFO (189 g, 1.06 mol)에 pyridine (4.19 g, 53.0 mmol)과 dichloromethane (933 mL)을 투입하고 -15~-10 ℃로 냉각하였다. Phosphorous trichloride (87.3 g, 636 mmol)를 천천히 투입하고 -15~-10 ℃에서 6시간 동안 추가 교반하였다. 반응이 완결되면 Sodium carbonate (5wt.% in water, 1.87 L)를 천천히 투입하고 상온으로 승온 후 유기층을 분리하였다. 수층을 dichloromethane (373 mL)로 추출하고 합해진 유기층을 magnesium sulfate로 처리하여 화합물 TIFCl (crude quant.)을 얻었다.Pyridine (4.19 g, 53.0 mmol) and dichloromethane (933 mL) were added to the compound TIFO (189 g, 1.06 mol) and cooled to -15 ~ -10 ℃. Phosphorous trichloride (87.3 g, 636 mmol) was slowly added, and the mixture was further stirred at -15 to -10 °C for 6 hours. When the reaction was completed, sodium carbonate (5wt.% in water, 1.87 L) was slowly added and the temperature was raised to room temperature, and the organic layer was separated. The aqueous layer was extracted with dichloromethane (373 mL), and the combined organic layer was treated with magnesium sulfate to obtain the compound TIFCl (crude quant.).
화합물 TIFN 제조 (NaCN)Preparation of compound TIFN (NaCN)
Figure PCTKR2021004719-appb-img-000017
Figure PCTKR2021004719-appb-img-000017
상온에서 화합물 TIFCl과 dimethyl sulfoxide (1.03 L)의 용액에 Sodium cyanide (104 g, 2.12 mol)를 투입하고 30~35 ℃로 승온하여 4시간 동안 교반하였다. 반응이 완료되면 물 (2.06 L)로 희석하고 ethyl acetate (824 mL, 412 mL)로 추출하였다. 합해진 유기층은 sodium chloride (26wt.% in water, 1.03 L x 2)로 세척하고, magnesium sulfate로 처리하여 화합물 TIFN (crude quant.)을 얻었다. Sodium cyanide (104 g, 2.12 mol) was added to a solution of the compound TIFCl and dimethyl sulfoxide (1.03 L) at room temperature, and the temperature was raised to 30-35 ℃ and stirred for 4 hours. When the reaction was completed, it was diluted with water (2.06 L) and extracted with ethyl acetate (824 mL, 412 mL). The combined organic layer was washed with sodium chloride (26wt.% in water, 1.03 L x 2) and treated with magnesium sulfate to obtain a compound TIFN (crude quant.).
화합물 TIFC 제조 (염기, 예를 들어, NaOH)Compound TIFC preparation (base, e.g. NaOH)
Figure PCTKR2021004719-appb-img-000018
Figure PCTKR2021004719-appb-img-000018
화합물 TIFN, 물 (970 mL), dimethyl sulfoxide (39 mL)의 혼합액에 Sodium hydroxide (127 g, 3.18 mol)를 투입하고 100~102 ℃에서 16시간 동안 교반하였다. 반응이 완료되면 상온으로 냉각하고 methyl tert-butyl ether (388 mL x 2)로 세척하였다. 얻어진 수층에 활성탄 (29 g)을 투입하고 30분 동안 교반한 후 여과하였다. 여과액에 hydrochloric acid (353 g, 3.58 mol)를 투입하여 산성화하고 이때 생성된 결정을 여과하여 화합물 TIFC (146 g, 0.715 mol)를 얻었다.Sodium hydroxide (127 g, 3.18 mol) was added to a mixture of the compound TIFN, water (970 mL), and dimethyl sulfoxide (39 mL), and the mixture was stirred at 100-102 °C for 16 hours. When the reaction was completed, it was cooled to room temperature and washed with methyl tert -butyl ether (388 mL x 2). Activated carbon (29 g) was added to the obtained aqueous layer, stirred for 30 minutes, and then filtered. The filtrate was acidified by adding hydrochloric acid (353 g, 3.58 mol), and the resulting crystal was filtered to obtain the compound TIFC (146 g, 0.715 mol).
화합물 (R)-TIFC·(S)-PEA salt 제조 (Resolution)Preparation of compound (R)-TIFC·(S)-PEA salt (Resolution)
Figure PCTKR2021004719-appb-img-000019
Figure PCTKR2021004719-appb-img-000019
화합물 TIFC (145 g, 0.710 mol)에 acetone (3.5 L)를 투입하고 50~55 ℃로 승온하였다. (S)-Phenylethyl amine (86.0 g, 0.71 mol)을 투입하고 30분 동안 교반한 후 5~10 ℃로 천천히 냉각하였다. 석출된 고체를 여과하고 여과된 고체에 추가로 acetone (2.0 L)를 투입하여 결정화 공정을 반복하였다. 석출된 고체를 여과 건조하여 화합물 (R)-TIFC·(S)-PEA salt (89.5 g, 0.275 mol, optical purity > 98.5%)를 얻었다. Acetone (3.5 L) was added to the compound TIFC (145 g, 0.710 mol), and the temperature was raised to 50-55 °C. (S)-Phenylethyl amine (86.0 g, 0.71 mol) was added, stirred for 30 minutes, and then slowly cooled to 5-10 °C. The precipitated solid was filtered, and the crystallization process was repeated by adding acetone (2.0 L) to the filtered solid. The precipitated solid was filtered and dried to obtain compound (R)-TIFC·(S)-PEA salt (89.5 g, 0.275 mol, optical purity > 98.5%).
화합물 (R)-TIFC 제조 (de-salting)Compound (R)-TIFC preparation (de-salting)
Figure PCTKR2021004719-appb-img-000020
Figure PCTKR2021004719-appb-img-000020
화합물 (R)-TIFC·(S)-PEA salt (166 g, 0.509 mol)에 물 (312 mL), dichloromethane (520 mL), tetrahydrofuran (144 mL), hydrochloric acid (100 g)를 투입하고 30분 동안 교반하였다. 정치 후 유기층을 분리하고 magnesium sulfate 처리하여 화합물 (R)-TIFC (103 g, 0.503 mol)를 얻었다.Water (312 mL), dichloromethane (520 mL), tetrahydrofuran (144 mL), and hydrochloric acid (100 g) were added to compound (R)-TIFC·(S)-PEA salt (166 g, 0.509 mol) for 30 minutes stirred for a while. After standing, the organic layer was separated and treated with magnesium sulfate to obtain compound (R)-TIFC (103 g, 0.503 mol).
화합물 TIFC 제조 (Racemize) (염기, 예를 들어, NaOH)Compound TIFC Preparation (Racemize) (Base, eg NaOH)
Figure PCTKR2021004719-appb-img-000021
Figure PCTKR2021004719-appb-img-000021
위 resolution 공정의 여액을 모아 농축하고 물 (810 mL)과 sodium hydroxide (59.7 g, 1.49 mol)을 투입하고 30분 동안 교반하였다. 수용액을 methyl tert-butyl ether (324 mL)로 세척하고 교반하였다. 반응물을 냉각하고 methyl tert-butyl ether (230 mL x 2)로 세척한다. 수층을 활성탄 (15.0 g) 처리하고 산성화하여 화합물 TIFC (89.1 g, 0.436 mol)를 회수하였다.The filtrate of the above resolution process was collected and concentrated, and water (810 mL) and sodium hydroxide (59.7 g, 1.49 mol) were added and stirred for 30 minutes. The aqueous solution was washed with methyl tert -butyl ether (324 mL) and stirred. Cool the reaction and wash with methyl tert -butyl ether (230 mL x 2). The aqueous layer was treated with activated carbon (15.0 g) and acidified to recover compound TIFC (89.1 g, 0.436 mol).
화합물 TIFM 제조 (LAH)Compound TIFM preparation (LAH)
Figure PCTKR2021004719-appb-img-000022
Figure PCTKR2021004719-appb-img-000022
화합물 (R)-TIFC (102 g, 0.499 mol)와 tetrahydrofuran (510 mL)의 용액을 lithium aluminium hydride (37.9 g, 0.999 mol)와 tetrahydrofuran (510 mL)의 혼합물에 천천히 투입하고 65~68 ℃에서 3시간 동안 교반하였다. 반응이 완결되면 냉각하고 물 (40 mL), 15% sodium hydroxide (수용액, 40 mL), 물 (120 mL) 순서로 투입한다. 반응물을 6시간 동안 교반하고 생성된 고체를 여과하였다. 여과액을 농축하고 농축 잔류물에 dichloromethane (510 mL)을 투입하고 묽은 hydrochloric acid 수용액으로 세척한 후 magnesium sulfate로 처리하여 화합물 TIFM (crude quant.)을 얻었다.A solution of compound (R)-TIFC (102 g, 0.499 mol) and tetrahydrofuran (510 mL) was slowly added to a mixture of lithium aluminum hydride (37.9 g, 0.999 mol) and tetrahydrofuran (510 mL) and heated at 65 to 68 °C for 3 stirred for hours. When the reaction is complete, cool and add water (40 mL), 15% sodium hydroxide (aqueous solution, 40 mL), and water (120 mL) in this order. The reaction was stirred for 6 hours and the resulting solid was filtered. The filtrate was concentrated, dichloromethane (510 mL) was added to the concentrated residue, washed with a dilute aqueous hydrochloric acid solution, and treated with magnesium sulfate to obtain a compound TIFM (crude quant.).
화합물 TIFMM 제조 (MsCl)Preparation of compound TIFMM (MsCl)
Figure PCTKR2021004719-appb-img-000023
Figure PCTKR2021004719-appb-img-000023
화합물 TIFM, Et 3N (75.7 g, 0.748 mol), dichloromethane (475 mL)의 혼합액을 0~5 ℃로 냉각하고 methanesulfonyl chloride (74.3 g, 0.649 mol)를 천천히 투입하였다. 투입이 완료되면 반응물을 5~10 ℃에서 30분 동안 교반하고 상온으로 승온하여 2시간 추가 교반하였다. 반응이 완결되면 0~5 ℃로 다시 냉각하고 물 (475 mL)을 천천히 투입하였다. 혼합액을 30분 동안 교반한 후 유기층을 분리하였다. 수층은 dichloromethane (190 mL)로 추가 추출하고 앞의 유기층과 합하였다. 합해진 유기층을 magnesium sulfate로 처리하여 화합물 TIFMM (crude quant.)을 얻었다. A mixture of the compound TIFM, Et 3 N (75.7 g, 0.748 mol), and dichloromethane (475 mL) was cooled to 0-5 °C, and methanesulfonyl chloride (74.3 g, 0.649 mol) was slowly added thereto. When the input was completed, the reaction was stirred at 5-10 °C for 30 minutes, heated to room temperature, and stirred for an additional 2 hours. When the reaction was completed, it was cooled again to 0-5 °C, and water (475 mL) was slowly added thereto. After stirring the mixture for 30 minutes, the organic layer was separated. The aqueous layer was further extracted with dichloromethane (190 mL) and combined with the previous organic layer. The combined organic layer was treated with magnesium sulfate to obtain a compound TIFMM (crude quant.).
화합물 TIFA 제조 (NaCN)Compound TIFA preparation (NaCN)
Figure PCTKR2021004719-appb-img-000024
Figure PCTKR2021004719-appb-img-000024
Sodium cyanide (48.9 g, 0.998 mol)를 화합물 TIFMM과 dimethyl sulfoxide (670 mL)의 용액에 투입하고 55~60 ℃로 승온하여 교반하였다. 반응이 완료되면 물 (1.40 L)로 희석하고 ethyl acetate (540 mL, 270 mL)로 추출하였다. 합해진 유기층은 sodium chloride (26wt.% in water, 670 mL x 2)로 세척하고, magnesium sulfate로 처리하여 화합물 TIFA (crude quant.)를 얻었다.Sodium cyanide (48.9 g, 0.998 mol) was added to a solution of the compound TIFMM and dimethyl sulfoxide (670 mL), and the temperature was raised to 55 ~ 60 ℃ and stirred. When the reaction was completed, it was diluted with water (1.40 L) and extracted with ethyl acetate (540 mL, 270 mL). The combined organic layer was washed with sodium chloride (26wt.% in water, 670 mL x 2) and treated with magnesium sulfate to obtain a compound TIFA (crude quant.).
화합물 TIFEA 제조 (NaBH 4 및 BF 3)Preparation of compound TIFEA (NaBH 4 and BF 3 )
Figure PCTKR2021004719-appb-img-000025
Figure PCTKR2021004719-appb-img-000025
화합물 TIFA와 tetrahydrofuran (500 mL)의 용액을 0~5 ℃로 냉각하고 sodium borohydride (22.7 g, 0.600 mol)를 투입한다. 반응물을 10~15 ℃로 승온하고 boron trifluoride tetrahydrofuran complex (112 g, 0.801 mol)를 30분 동안 투입하였다. 투입이 완료되면 동일한 온도에서 30분 동안 교반한 후 60~65 ℃로 승온하여 12시간 동안 추가 교반하였다. 반응이 완료되면 5% hydrochloric acid (수용액, 110 mL)를 투입하고 60~65 ℃에서 8시간 동안 교반하였다. 이후 30% Sodium hydroxide (수용액, 320 mL)을 투입하고 12시간 동안 추가 교반한 후 상온으로 냉각하였다. 이후 유기층을 분리하고 농축하였다. 농축 잔류물에 toluene (1.0 L)을 투입하고 sodium chloride (26wt.% in water, 300 mL)로 세척하였다. 얻어진 유기층에 hydrochloric acid (167 g, 1.70 mol)를 투입한 후 30분 동안 교반하고 농축하였다. 농축 잔류물에 acetone (400 mL)을 투입하고 가온 교반 후 냉각하였다. 생성된 고체를 여과하고 여과 고체에 추가로 ethanol (50 mL)과 methyl tert-butyl ether (500 mL)를 투입하였다. 반응물을 가온 교반 후 냉각하고 생성된 고체를 여과하여 화합물 TIFEA (102 g, 0.425 mol)를 얻었다. 0-5 solution of compound TIFA and tetrahydrofuran (500 mL) Cool to ℃ and add sodium borohydride (22.7 g, 0.600 mol). 10 to 15 reactants The temperature was raised to ℃ and boron trifluoride tetrahydrofuran complex (112 g, 0.801 mol) was added for 30 minutes. When the input is completed, stir at the same temperature for 30 minutes and then 60~65 The temperature was raised to ℃ and further stirred for 12 hours. When the reaction was completed, 5% hydrochloric acid (aqueous solution, 110 mL) was added and stirred at 60-65 °C for 8 hours. Then, 30% sodium hydroxide (aqueous solution, 320 mL) was added, and the mixture was further stirred for 12 hours and then cooled to room temperature. Then, the organic layer was separated and concentrated. Toluene (1.0 L) was added to the concentrated residue and washed with sodium chloride (26wt.% in water, 300 mL). After adding hydrochloric acid (167 g, 1.70 mol) to the obtained organic layer, the mixture was stirred for 30 minutes and concentrated. Acetone (400 mL) was added to the concentrated residue, and after heating and stirring, it was cooled. The resulting solid was filtered, and ethanol (50 mL) and methyl tert- butyl ether (500 mL) were added to the filtered solid. The reaction product was warmed and stirred, cooled, and the resulting solid was filtered to obtain the compound TIFEA (102 g, 0.425 mol).
Ramelteon 제조 (Propionyl chloride)Manufactured by Ramelteon (Propionyl chloride)
Figure PCTKR2021004719-appb-img-000026
Figure PCTKR2021004719-appb-img-000026
화합물 TIFEA (90.0 g, 0.375 mol)에 tetrahydrofuran (225 mL)과 물 (315 mL)을 투입하고 30% sodium hydroxide (수용액, 85.0 mL, 0.848 mol)를 투입하였다. 반응액을 10~15 ℃로 냉각하고 propionyl chloride (40.0 g, 0.432 mol)를 천천히 투입하였다. 투입이 완료되면 15~25 ℃에서 1시간 동안 추가 교반하였다. 반응액에 물 (720 mL)을 투입한 후 0~5 ℃로 냉각하고 생성된 고체를 여과하였다. 얻어진 고체는 ethanol과 물의 혼합용매에서 재결정 정제하여 Ramelteon (87.6 g, 0.338 mol)을 얻었다.Tetrahydrofuran (225 mL) and water (315 mL) were added to the compound TIFEA (90.0 g, 0.375 mol), and 30% sodium hydroxide (aqueous solution, 85.0 mL, 0.848 mol) was added. The reaction solution was cooled to 10 ~ 15 ℃, propionyl chloride (40.0 g, 0.432 mol) was slowly added. When the input was completed, the mixture was further stirred at 15-25 °C for 1 hour. After adding water (720 mL) to the reaction solution, it was cooled to 0-5 °C, and the resulting solid was filtered. The obtained solid was recrystallized and purified in a mixed solvent of ethanol and water to obtain Ramelteon (87.6 g, 0.338 mol).

Claims (14)

  1. 하기 화학식 1의 화합물.A compound of Formula 1 below.
    [화학식 1][Formula 1]
    Figure PCTKR2021004719-appb-img-000027
    Figure PCTKR2021004719-appb-img-000027
  2. 제1항에 있어서, 상기 화합물은 (R)-이성질체 형태인, 화합물. The compound of claim 1 , wherein the compound is in the (R)-isomeric form.
  3. 제1항에 있어서, 상기 화합물은 (S)-이성질체 형태인, 화합물.The compound of claim 1 , wherein the compound is in the (S)-isomeric form.
  4. 하기 화학식 2의 카이럴 아민 염(chiral amine salt) 화합물.A chiral amine salt compound of Formula 2 below.
    [화학식 2][Formula 2]
    Figure PCTKR2021004719-appb-img-000028
    Figure PCTKR2021004719-appb-img-000028
  5. 제4항에 있어서, 상기 카이럴 아민(chiral amine)은 (S)-phenylethylamine, L-(-)-α-Amino-ε-caprolactam hydrochloride, ( S)-(-)-1-Amino-2-propanol, L-Aspartic acid, ( S)- N-Benzyl-1-(1-naphthyl)ethylamine hydrochloride, (+)-Bis[( R)-1-phenylethyl]amine hydrochloride, (+)-Cinchonine, ( R)-α-Methyl-4-nitrobenzylamine hydrochloride 또는 ( S)-(-)-1-(2-Naphthyl)ethylamine인 화합물. 5. The method of claim 4, wherein the chiral amine is (S)-phenylethylamine, L-(-)-α-Amino-ε-caprolactam hydrochloride, ( S )-(-)-1-Amino-2- propanol, L-Aspartic acid, ( S) - N -Benzyl-1- (1-naphthyl) ethylamine hydrochloride, (+) - Bis [(R) -1-phenylethyl] amine hydrochloride, (+) - Cinchonine, (R )-α-Methyl-4-nitrobenzylamine hydrochloride or ( S )-(-)-1-(2-Naphthyl)ethylamine.
  6. 하기 화학식 3의 (R)-이성질체 화합물.(R)-isomer compound of formula (3).
    [화학식 3][Formula 3]
    Figure PCTKR2021004719-appb-img-000029
    Figure PCTKR2021004719-appb-img-000029
  7. 하기 화학식 1의 (R)-이성질체를 이용하는 것을 특징으로 하는 라멜테온(ramelteon)의 제조 방법.A method for producing a ramelteon, characterized in that using the (R)-isomer of the following formula (1).
    [화학식 1][Formula 1]
    Figure PCTKR2021004719-appb-img-000030
    Figure PCTKR2021004719-appb-img-000030
  8. 제7항에 있어서, 상기 방법은 라세믹 화합물인 1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-carboxylic acid를 광학분할(optical resolution)하여 화학식 1의 (R)-이성질체를 획득하는 단계를 포함하는, 제조 방법.According to claim 7, wherein the method is a racemic compound 1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-carboxylic acid by optical resolution (optical resolution) of Formula 1 (R) -A method of preparation comprising the step of obtaining an isomer.
  9. 제8항에 있어서, 상기 광학분할은 카이럴 아민 염(chiral amine salt)을 형성하여 수행되는, 제조 방법.The method of claim 8, wherein the optical resolution is performed by forming a chiral amine salt.
  10. 제9항에 있어서, 상기 카이럴 아민(chiral amine)은 (S)-phenylethylamine, L-(-)-α-Amino-ε-caprolactam hydrochloride, ( S)-(-)-1-Amino-2-propanol, L-Aspartic acid, ( S)- N-Benzyl-1-(1-naphthyl)ethylamine hydrochloride, (+)-Bis[( R)-1-phenylethyl]amine hydrochloride, (+)-Cinchonine, ( R)-α-Methyl-4-nitrobenzylamine hydrochloride 또는 ( S)-(-)-1-(2-Naphthyl)ethylamine인, 제조 방법.The method of claim 9, wherein the chiral amine is (S)-phenylethylamine, L-(-)-α-Amino-ε-caprolactam hydrochloride, ( S )-(-)-1-Amino-2- propanol, L-Aspartic acid, ( S) - N -Benzyl-1- (1-naphthyl) ethylamine hydrochloride, (+) - Bis [(R) -1-phenylethyl] amine hydrochloride, (+) - Cinchonine, (R )-α-Methyl-4-nitrobenzylamine hydrochloride or ( S )-(-)-1-(2-Naphthyl)ethylamine.
  11. 제9항에 있어서, 상기 방법은 광학분할 과정에서 회수되는 화학식 1의 (S)-이성질체의 카이럴 아민 염을 라세미화(ramcemize)하여 다시 이용하는, 제조 방법.The method according to claim 9, wherein the method uses the chiral amine salt of the (S)-isomer of formula (1) recovered during the optical resolution process by racemization and reuse.
  12. 제11항에 있어서, 상기 라세미화는 염기 하에서 이루어지는, 제조 방법.The method according to claim 11, wherein the racemization is carried out under a base.
  13. 제12항에 있어서, 상기 염기는 NaOH (sodium hydroxide), KOH (potassium hydroxide), KOtBu (potassium tert-butoxide), NaOMe (sodium methoxide) 또는 이들의 혼합물인, 제조 방법. The method according to claim 12, wherein the base is sodium hydroxide (NaOH), potassium hydroxide (KOH), potassium tert-butoxide (KOtBu), sodium methoxide (NaOMe), or a mixture thereof.
  14. 제7항 내지 제13항 중 어느 한 항에 있어서, 상기 방법은 화학식 1의 (S)-이성질체로 화학식 3의 화합물로 제조하는 과정을 포함하는, 제조 방법.The method according to any one of claims 7 to 13, wherein the method comprises preparing the compound of formula (3) as the (S)-isomer of formula (1).
    [화학식 1][Formula 1]
    Figure PCTKR2021004719-appb-img-000031
    Figure PCTKR2021004719-appb-img-000031
    [화학식 3][Formula 3]
    Figure PCTKR2021004719-appb-img-000032
    Figure PCTKR2021004719-appb-img-000032
PCT/KR2021/004719 2020-04-16 2021-04-14 Method for producing ramelteon, and intermediate compound used for same WO2021210920A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020200046248A KR102359229B1 (en) 2020-04-16 2020-04-16 A method for manufacturing ramelteon and intermediate compounds used therein
KR10-2020-0046248 2020-04-16

Publications (1)

Publication Number Publication Date
WO2021210920A1 true WO2021210920A1 (en) 2021-10-21

Family

ID=78084815

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2021/004719 WO2021210920A1 (en) 2020-04-16 2021-04-14 Method for producing ramelteon, and intermediate compound used for same

Country Status (2)

Country Link
KR (1) KR102359229B1 (en)
WO (1) WO2021210920A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230286950A1 (en) * 2022-02-04 2023-09-14 Aclaris Therapeutics, Inc. Methods of synthesizing deuterated substituted pyridinone-pyridinyl compounds

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008151170A2 (en) * 2007-05-31 2008-12-11 Teva Pharmaceutical Industries Ltd. Process for the synthesis of ramelteon and its intermediates
CN101654445A (en) * 2008-08-22 2010-02-24 四川大学 Compound for preparing ramelteon, preparation method thereof and application thereof
CN102391220A (en) * 2011-10-10 2012-03-28 四川大学 Tricyclic ethanol compound, as well as preparation method and usages thereof
CN106749131A (en) * 2015-11-20 2017-05-31 上海医药工业研究院 Racemization prepares ramelteon intermediate method
CN110818720A (en) * 2019-11-19 2020-02-21 上海阳帆医药科技有限公司 Melatonin (MT1/MT2) receptor agonist, preparation method and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034239A (en) 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
JP4081161B2 (en) 1997-09-05 2008-04-23 武田薬品工業株式会社 Method for producing optically active compound
TWI400220B (en) 2004-09-13 2013-07-01 Takeda Pharmaceutical Process for producing optically active amine derivatives

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008151170A2 (en) * 2007-05-31 2008-12-11 Teva Pharmaceutical Industries Ltd. Process for the synthesis of ramelteon and its intermediates
CN101654445A (en) * 2008-08-22 2010-02-24 四川大学 Compound for preparing ramelteon, preparation method thereof and application thereof
CN102391220A (en) * 2011-10-10 2012-03-28 四川大学 Tricyclic ethanol compound, as well as preparation method and usages thereof
CN106749131A (en) * 2015-11-20 2017-05-31 上海医药工业研究院 Racemization prepares ramelteon intermediate method
CN110818720A (en) * 2019-11-19 2020-02-21 上海阳帆医药科技有限公司 Melatonin (MT1/MT2) receptor agonist, preparation method and application thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230286950A1 (en) * 2022-02-04 2023-09-14 Aclaris Therapeutics, Inc. Methods of synthesizing deuterated substituted pyridinone-pyridinyl compounds

Also Published As

Publication number Publication date
KR20210128263A (en) 2021-10-26
KR102359229B1 (en) 2022-02-07

Similar Documents

Publication Publication Date Title
AU2018385820B2 (en) Intermediates for optically active piperidine derivatives and preparation methods thereof
WO2020027415A1 (en) Method for producing lithium difluorophosphate crystal in high purity and non-aqueous electrolyte for secondary battery using same
WO2010150946A1 (en) Method for preparation of carbamic acid (r)-1-aryl-2-tetrazolyl-ethyl ester
WO2009134030A1 (en) Novel process for preparation of iopromide
WO2017023123A1 (en) Novel method for preparing chromanone derivative
WO2009096668A2 (en) Improved process for preparing mycophenolate mofetil
WO2022244969A1 (en) Method for preparing methylene lactone-based compound
AU2018308164B2 (en) Intermediates useful for the synthesis of a selective inhibitor against protein kinase and processes for preparing the same
WO2021210920A1 (en) Method for producing ramelteon, and intermediate compound used for same
WO2013061247A1 (en) Novel process for the preparation of asenapine
WO2010036048A2 (en) Method for preparing montelukast sodium salts
WO2022164150A1 (en) Nafamostat mesylate and method for producing intermediate thereof
WO2012050263A1 (en) Novel method of preparing endoxifen
WO2013141437A1 (en) Method for manufacturing high purity (s)-metoprolol
EP3535237A1 (en) Method for preparation of (s)-n1-(2-aminoethyl)-3-(4-alkoxyphenyl)propane-1,2-diamine trihydrochloride
WO2015060657A1 (en) A method for preparing an intermediate of iopromide
WO2020166984A1 (en) Intermediate for producing phenazine derivative, and method for producing same
WO2021107514A2 (en) Method for preparing lifitegrast
WO2017074147A1 (en) Novel process for preparing thienopyrimidine compound and intermediates used therein
WO2019031774A1 (en) Method for preparing latanoprostene bunod, and intermediate therefor
WO2019124674A1 (en) N-substituted maleimide purification method
WO2019117446A1 (en) Method for producing 2-octylglycine ester having optical activity
WO2022149638A1 (en) Pyrrolopyridine derivative preparation method
CN111848419B (en) (E) Synthesis method of (E) -4-hydroxy-3-methyl-2-butenylamine and zeatin
WO2023013973A1 (en) Novel method for preparing rucaparib

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21789105

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21789105

Country of ref document: EP

Kind code of ref document: A1